Progyny, Inc. (NASDAQ:PGNY) CEO Buys $3,033,560.00 in Stock

Progyny, Inc. (NASDAQ:PGNY) CEO Peter Anevski bought 209,500 shares of Progyny stock in a transaction dated Monday, December 23rd. The stock was purchased at an average price of $14.48 per share, with a total value of $3,033,560.00. Following the purchase, the chief executive officer now owns 441,463 shares in the company, valued at approximately $6,392,384.24. This represents a 90.32 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Progyny Stock Up 14.9 %

NASDAQ PGNY opened at $16.90 on Friday. The company’s 50 day moving average is $15.23 and its 200-day moving average is $20.46. The firm has a market cap of $1.44 billion, a P/E ratio of 29.14, a price-to-earnings-growth ratio of 1.64 and a beta of 1.35. Progyny, Inc. has a 12-month low of $13.39 and a 12-month high of $42.08.

Progyny (NASDAQ:PGNY) last issued its earnings results on Tuesday, November 12th. The company reported $0.11 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.26). Progyny had a net margin of 5.03% and a return on equity of 11.36%. The business had revenue of $286.63 million for the quarter, compared to the consensus estimate of $296.85 million. During the same period in the previous year, the firm earned $0.16 EPS. The company’s revenue was up 2.0% compared to the same quarter last year. Equities analysts expect that Progyny, Inc. will post 0.59 EPS for the current year.

Wall Street Analyst Weigh In

PGNY has been the subject of a number of recent analyst reports. Bank of America reduced their price objective on shares of Progyny from $22.00 to $21.00 and set a “buy” rating for the company in a research report on Wednesday, November 13th. JMP Securities downgraded Progyny from an “outperform” rating to a “market perform” rating in a research report on Thursday, September 19th. Jefferies Financial Group cut their price objective on Progyny from $31.00 to $24.00 and set a “buy” rating on the stock in a research report on Thursday, September 19th. Truist Financial reaffirmed a “hold” rating and set a $19.00 target price (down from $26.00) on shares of Progyny in a research report on Wednesday, November 13th. Finally, Canaccord Genuity Group cut their price target on shares of Progyny from $18.00 to $17.00 and set a “hold” rating on the stock in a report on Wednesday, November 13th. Nine investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $25.00.

Institutional Trading of Progyny

Institutional investors have recently added to or reduced their stakes in the stock. Franklin Resources Inc. increased its position in shares of Progyny by 17.0% during the third quarter. Franklin Resources Inc. now owns 48,248 shares of the company’s stock valued at $759,000 after buying an additional 7,003 shares during the period. Tidal Investments LLC increased its holdings in Progyny by 67.7% during the 3rd quarter. Tidal Investments LLC now owns 60,722 shares of the company’s stock worth $1,018,000 after acquiring an additional 24,507 shares during the period. Disciplined Growth Investors Inc. MN increased its holdings in Progyny by 56.5% during the 3rd quarter. Disciplined Growth Investors Inc. MN now owns 826,726 shares of the company’s stock worth $13,856,000 after acquiring an additional 298,314 shares during the period. Barclays PLC lifted its stake in Progyny by 530.4% in the 3rd quarter. Barclays PLC now owns 706,157 shares of the company’s stock worth $11,835,000 after purchasing an additional 594,140 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd bought a new position in Progyny in the 3rd quarter valued at $469,000. Hedge funds and other institutional investors own 94.93% of the company’s stock.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.